FDA Approves Belzutifan for Pheochromocytoma or Paraganglioma By Ogkologos - June 6, 2025 812 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LITESPARK-015 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Adjuvant Atezolizumab Plus Bevacizumab Improves RFS Among Patients at High Risk... November 16, 2023 Pump Up the Volume: “Priming Agents” May Improve Cancer Liquid Biopsies February 22, 2024 New Safety Signal for Use of Ibrutinib in Combination with Rituximab... September 15, 2021 FDA Proposes Rule Prohibiting Menthol Cigarettes June 27, 2022 Load more HOT NEWS Running a cancer helpline in COVID-19: two years on the virtual... Common anti-inflammatory drug could boost cancer immunotherapy Should People With Cancer Be Tested for Hepatitis B? Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy,...
